Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sintilimab + mFFN + NALIRIFOX
- Development stage
- Unknown
- Lead developer
- Shandong Cancer Hospital
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Sintilimab + mFFN + NALIRIFOX is a combination chemo-immunotherapy regimen being investigated for the treatment of unresectable locally advanced pancreatic cancer. The regimen consists of sintilimab, a recombinant humanized IgG4 monoclonal antibody that binds to the programmed cell death protein 1 (PD-1) receptor, blocking its interaction with PD-L1 and PD-L2 to restore T-cell mediated anti-tumor activity. This is combined with one of two chemotherapy backbones: modified FOLFIRINOX (mFFN), which includes fluorouracil, leucovorin, irinotecan, and oxaliplatin; or NALIRIFOX, which substitutes standard irinotecan with nanoliposomal irinotecan. The regimen is typically administered in conjunction with radiotherapy. It is currently being evaluated in a Phase II clinical trial sponsored by the Shandong Cancer Hospital and Institute.
- Brand names
- Onivyde
- Other names
- Sintilimab Plus mFFN or NALIRIFOX and RadiationSintilimab Plus Chemotherapy and Radiotherapy for Patients With Inoperable Pancreatic Cancer
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)DNATOP1 (DNA Topoisomerase I)TS (Thymidylate synthase)
Beyond the preview
Go deeper on sintilimab + mFFN + NALIRIFOX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sintilimab + mFFN + NALIRIFOX.